Structure via PubChem · Public domain (PubChem)
axitinib
Sign in to saveAlso known as AG 013736, AG-013736, AG013736, Inlyta®, N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide, axitinibum
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
In the Vinony graph
Vinony's link graph records 502 inbound references to axitinib, and connects out to KIT proto-oncogene, receptor tyrosine kinase, VEGF receptors and United States Food and Drug Administration.
Vinony files it under 2-Pyridyl compounds, Alkene derivatives and Benzamides.
Vinony links it to 13 Wikipedia language editions.
Chemical data
- Formula
- C22H18N4OS
- Molecular weight
- 386.5 g/mol
- IUPAC name
- N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
- SMILES
- CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
- InChIKey
- RITAVMQDGBJQJZ-FMIVXFBMSA-N
- XLogP
- 4.2
- Polar surface area
- 96 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2012
- Admin. routes
- oral
- Indications
- neoplasm, renal cell carcinoma, adenoid cystic carcinoma, carcinoid tumor
via ChEMBL · EBI
Research
2,007 papers- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.The New England journal of medicine · 2019
- Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
- Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.European urology · 2023
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.The Lancet. Oncology · 2020
- Axitinib (AG-013736).Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2010
via PubMed
Wikidata facts
- Mass
- 386.12
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₂H₁₈N₄OS
- isomeric SMILES
- CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
- canonical SMILES
- CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
- World Health Organisation international non-proprietary name
- axitinib
- subject has role
- protein kinase inhibitors
- Commons category
- Axitinib
via Wikidata · CC0
~5 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Renal cell carcinoma
- Clinical trials
- Adverse effects
- Interactions
- Mechanism of action
- Pharmacokinetics
- Society and culture
- Legal status
- Economics
- Brand names
- References
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
It was approved to treat renal cell carcinoma by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.
Excerpted from Wikipedia’s “axitinib” article, available under the CC BY-SA 4.0 licence.